目的 分析银杏酮酯分散片对脑卒中患者血清炎症因子水平、神经功能改善情况。方法 本研究对象选取92例脑卒中患者，按照随机数字表法分成对照组和观察组各46例。对照组患者给予常规治疗，观察组患者在此基础上辅以银杏酮酯分散片口服治疗。连续治疗14 d，对比两组治疗前后血清炎症因子水平、血脂水平、神经功能缺损程度、认知功能、不良反应的差异。结果 治疗前两组患者血清白介素-8（IL-8）、白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）水平无统计学差异；治疗后两组IL-8、IL-6、TNF-α水平均明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组血清IL-8、IL-6、TNF-α水平低于对照组，组间有显著的统计学差异（P<0.05）。治疗前两组患者血脂水平无统计学差异；治疗后对照组TC明显降低，HDL-C明显升高，差异有统计学意义（P<0.05）；观察组TG、TC、LDL-C低于对照组，HDL-C高于对照组，组间差异有统计学意义（P<0.05）。治疗前两组患者NIHSS评分、MMSE评分无统计学差异；治疗后两组NIHSS评分均降低，MMSE评分均升高，同组治疗前后比较差异有统计学意义（P<0.05）；观察组NIHSS评分低于对照组、MMSE评分高于对照组，组间差异有统计学意义（P<0.05）。治疗期间两组均未见不良反应报告。结论 银杏酮酯分散片可降低脑卒中患者血清中促炎症因子水平、调节血脂水平、减轻神经功能缺损程度、改善认知功能，且无明显不良反应，值得临床推广应用。

Objective To analyze the serum levels of inflammatory factors and neurological function in patients with stroke treated with Ginkgo biloba extract dispersible tablets.Methods 92 stroke patients were randomly divided into the control group and the observation group, with 46 cases in each group. Patients in the control group were given conventional treatment, and the observation group was treated with Ginkgo acetate dispersible tablets on the basis of oral treatment. The serum levels of inflammatory factors, blood lipid levels, neurological impairment, cognitive function and adverse reactions were compared between the two groups before and after treatment with 14 d.Results Before treatment, two groups of patients with serum IL-8, IL-6 and TNF-levels had no significant difference; after treatment, serum IL-8, IL-6, TNF-levels lower than the control group, there was a significant difference between the groups (P < 0.05). There was no significant difference in serum lipid level between the two groups before treatment. After treatment, the TG, TC and LDL-C in the observation group were lower than that in the control group, and HDL-C was higher than that in the control group, and there was a statistically significant difference between the two groups (P < 0.05). Two groups of patients with NIHSS score and MMSE score had no significant difference before treatment; after treatment, NIHSS score of observation group was lower than that of the control group, MMSE score higher than the control group, there was a significant difference between the groups (P < 0.05). There were no adverse reactions in the two groups during the treatment.Conclusion Ginkgo biloba dispersible tablets can reduce the level of inflammatory factors, regulating blood lipid level, reduce the degree of neurological deficit, improve cognitive function of patients with stroke in serum, and no obvious adverse reactions, it is worthy of clinical application.